FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy

Lignende værker

• FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
  af: Pai‐Scherf, Lee, et al.
  Udgivet: (2017)
• FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
  af: Sul, Joohee, et al.
  Udgivet: (2016)
• FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
  af: Bhatnagar, Vishal, et al.
  Udgivet: (2017)
• FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
  af: Kazandjian, Dickran, et al.
  Udgivet: (2016)
• FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
  af: Suzman, Daniel L., et al.
  Udgivet: (2018)